Home › Research › Treatments
Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study
Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I.. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 2021-12-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Behavioral and psychological symptoms of dementia (BPSD) are common in individuals with Alzheimer disease (AD). Donepezil and memantine are both widely used for the treatment of moderate AD. Objective To evaluate the effects of donepezil and memantine in relieving BPSD in individuals with moderate AD. Method We conducted a prospective, randomized, 6-month clinical trial involving 85 individuals with moderate AD divided into two groups: group 1 (n = 42) was treated with donepezil; group 2 (n = 43) was treated with memantine. We used the Neuropsychiatric Inventory (NPI) to assess the prevalence and severity of BPSD at baseline and after 6 months of treatment with donepezil or memantine. Results The two groups' baseline characteristics, including age, sex, mean length of education, and disease duration, were comparable, as were their baseline Mini-Mental State Examination scores. The NPI Total score improved from baseline to month 6 in both groups (P Conclusion Specific drugs for AD, including donepezil and memantine, may be effective in treating BPSD in individuals with moderate AD, with a favorable safety profile.
What this study adds
Evidence grade: High
This is a trial of 42 participants. In this six-month trial of 85 people with moderate Alzheimer's disease, behavioral and psychological symptom scores improved from baseline in both the donepezil and memantine groups. The authors conclude these drugs may be effective for such symptoms with a favorable safety profile, though this addresses symptom relief rather than curing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bago Rožanković, P., Rožanković, M., Badžak, J., Stojić, M., & Šušak Sporiš, I. (2021). Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. https://doi.org/10.1097/wnn.0000000000000285
Vancouver
Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. 2021. doi:10.1097/wnn.0000000000000285. PMID: 34851866.
BibTeX
@article{bagorozankovic2021-34851866,
author = {Bago Rožanković, P. and Rožanković, M. and Badžak, J. and Stojić, M. and Šušak Sporiš, I.},
title = {{Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study}},
journal = {Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology},
year = {2021},
doi = {10.1097/wnn.0000000000000285},
pmid = {34851866},
url = {https://doi.org/10.1097/wnn.0000000000000285}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results The two groups' baseline characteristics, including age, sex, mean length of education, and disease duration, were comparable, as were their baseline Mini-Mental State Examination scores.
Why it matters
In this six-month trial of 85 people with moderate Alzheimer's disease, behavioral and psychological symptom scores improved from baseline in both the donepezil and memantine groups. The authors conclude these drugs may be effective for such symptoms with a favorable safety profile, though this addresses symptom relief rather than curing the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants42
- Evidence strengthHigh
How this study scored 51/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology) |
| Journal's citation record | 0 / 4 | Cognitive and Behavioral Neurology: journal h-index 66 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 42 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 3 / 7 | Cited 18 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.6 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 2 / 6 | Cited 1.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Ivana Šušak Sporiš: h-index 4 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University Hospital Centre Zagreb: institution h-index 259 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34851866) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.